Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P210034/S001

Agili-C

Smith and Nephew, Inc. · Decision date Jun 4, 2026

FDA DECISIONP210034/S001

What did the FDA approve?

FDA records P210034/S001 as a supplement to PMA P210034, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jun 4, 2026.

FDA approval order statement

Approval for updated package labeling that incorporates the clinical results from the required postapproval study.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Orthopedic
Decision date
Jun 4, 2026
FDA change category
Labeling Change - PAS

FDA source record

Regulatory record facts

Identifier
P210034/S001
Regulatory pathway
PMA supplement
Product code
QRU
Decision code
APPR
Decision date
Jun 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, resorbable, for articular osteochondral repair.

Product code
QRU
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P210034/S001 received

    Application receipt date recorded by FDA.

  2. P210034/S001 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P210034. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Smith and Nephew, Inc.

Headquarters
Not reported
Brand website
smith-nephew.com
FDA applicant address
150 Minuteman Rd., Andover, MA, 01810

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records